Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLO severe hepatic impairment dolutegravir pharmacokinetics study
NL-OMON47050Phase 4Withdrawn
- Sponsor
- Ziekenhuisapotheek
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dolutegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Ziekenhuisapotheek. Primary endpoints: Dolutegravir pharmacokinetics, Dolutegravir glucuronide pharmacokinetics and 1 more. Planned start Oct 2017; status: withdrawn.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON47050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47050.